Incannex Healthcare Inc.
IXHL Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$2.61
KIRA · Stoqly’s AI analyst, in plain words
- Incannex Healthcare Inc. had $0.0M of revenue in fiscal 2026, down 100.0% on the year before.
- Incannex Healthcare Inc. lost $19.3M in fiscal 2026.
- Free cash flow was −$12.9M in fiscal 2026, — of revenue.
- Incannex Healthcare Inc. returned $9.4M to shareholders in fiscal 2026. The diluted share count rose 915.1%.
Market cap
$30.4M
P/E
—
Revenue
$0.0M
Net income
−$19.3M
Free cash flow
−$12.9M
Operating margin
—
Incannex Healthcare Inc. in 30 seconds · fiscal 2026
Are sales growing?
−100.0%
No. Sales fell 100.0% last year.
Does it make a profit?
−$19.3M
No. It lost money last year.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Incannex Healthcare Inc. does
No business description yet.
- Fiscal year ends
- June 30, 2026
- Latest annual report
- 10-K · Sep 25, 2026
- Legal name
- Incannex Healthcare Inc.
- CIK
- 0001873875
Incannex Healthcare Inc. · IXHL
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Sales and profit | ||||
| Revenue | — | $0.0M | $0.1M | $0.0M |
| Revenue growth | — | — | 616.7% | −100.0% |
| Operating margin | — | −250,341.7% | −27,661.6% | — |
| Net income | −$48.8M | −$18.5M | −$46.9M | −$19.3M |
| Net margin | — | −153,825.0% | −54,517.4% | — |
| Diluted EPS | −$3.32 | −$1.15 | −$40.82 | −$1.66 |
| Cash | ||||
| Cash from operations | −$10.7M | −$15.8M | −$12.5M | −$12.9M |
| Capital expenditure | $0.3M | $0.3M | $0.0M | $0.0M |
| Free cash flow | −$11.1M | −$16.1M | −$12.5M | −$12.9M |
| FCF margin | — | −134,350.0% | −14,559.3% | — |
| Share buybacks | — | — | $0.0M | $9.4M |
| Share count change | — | 5.1% | −92.9% | 915.1% |
| Debt and strength | ||||
| Cash and short-term investments | $22.1M | $5.9M | $15.0M | $67.7M |
| Shareholders' equity | $20.8M | $11.2M | $13.4M | $67.4M |
| Current ratio | 9.0x | 2.9x | 2.9x | 48.8x |
| Interest coverage | — | — | −78.5x | — |
| Returns and quality | ||||
| Return on equity | −234.4% | −115.2% | −381.1% | −47.8% |
| Return on tangible equity | −234.4% | −164.6% | −350.2% | −28.6% |
| Piotroski F-score | — | — | 3 | 3 |
| Altman Z'' | −13.6 | −26.9 | −26.8 | 9.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Incannex Healthcare Inc. · IXHL
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.61 a share, the company is worth $30.4M.
Source: SEC EDGAR XBRL filings (CIK 0001873875). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.